CN102648279B - 用于治疗药物诱发的手足综合征的组合物与方法 - Google Patents

用于治疗药物诱发的手足综合征的组合物与方法 Download PDF

Info

Publication number
CN102648279B
CN102648279B CN201080057133.2A CN201080057133A CN102648279B CN 102648279 B CN102648279 B CN 102648279B CN 201080057133 A CN201080057133 A CN 201080057133A CN 102648279 B CN102648279 B CN 102648279B
Authority
CN
China
Prior art keywords
ppe
drug
patient
phosphodiesterase inhibitor
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080057133.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102648279A (zh
Inventor
H.赫维茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of CN102648279A publication Critical patent/CN102648279A/zh
Application granted granted Critical
Publication of CN102648279B publication Critical patent/CN102648279B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080057133.2A 2009-10-16 2010-10-15 用于治疗药物诱发的手足综合征的组合物与方法 Active CN102648279B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27909109P 2009-10-16 2009-10-16
US61/279091 2009-10-16
PCT/US2010/052836 WO2011047256A1 (en) 2009-10-16 2010-10-15 Compositions and methods for the treatment of drug-induced hand-foot syndrome

Publications (2)

Publication Number Publication Date
CN102648279A CN102648279A (zh) 2012-08-22
CN102648279B true CN102648279B (zh) 2015-11-25

Family

ID=43876575

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080057133.2A Active CN102648279B (zh) 2009-10-16 2010-10-15 用于治疗药物诱发的手足综合征的组合物与方法

Country Status (6)

Country Link
US (2) US9220713B2 (https=)
EP (1) EP2488642B1 (https=)
JP (2) JP2013508295A (https=)
CN (1) CN102648279B (https=)
AU (1) AU2010306671B2 (https=)
WO (1) WO2011047256A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508295A (ja) * 2009-10-16 2013-03-07 デューク・ユニヴァーシティ 薬物誘発性手足症候群を治療するための組成物および方法
GB2503181A (en) * 2011-03-14 2013-12-18 Cellworks Res India Private Ltd Compositions, process of preparation of said compositions and method of treating inflammatory diseases
CA2914815A1 (en) * 2013-06-11 2014-12-18 Kala Pharmaceuticals, Inc. Urea derivatives and uses thereof
WO2016144230A1 (en) * 2015-03-06 2016-09-15 Telefonaktiebolaget Lm Ericsson (Publ) Method, network device, computer program and computer program product for mobile service chaining
CA3071071A1 (en) * 2017-08-18 2019-02-21 The Procter & Gamble Company Method of cleaning
JP2021506958A (ja) 2017-12-13 2021-02-22 オンクォリティ ファーマシューティカルズ チャイナ エルティーディーＯｎｑｕａｌｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｈｉｎａ Ｌｔｄ． Ｅｇｆｒ阻害に関連する疾患を予防又は治療する方法
KR102831159B1 (ko) 2018-04-16 2025-07-07 온퀄리티 파마슈티컬스 차이나 리미티드 암 치료의 부작용을 예방하거나 치료하기 위한 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9019A (en) * 1852-06-15 Charles fleischbl
US9004A (en) * 1852-06-08 Improvement in seed-planters
US2002A (en) * 1841-03-12 Tor and planter for plowing
US20020028237A1 (en) 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
MXPA03006936A (es) * 2001-02-02 2003-11-18 Pfizer Tratamiento de diabetes mellitus.
US20090048179A1 (en) * 2005-02-22 2009-02-19 Cedars-Sinai Medical Center Use of 5-phosphodiesterase inhibitors to enhance the permeability of the blood-brain barrier of abnormal brain tissue and the blood-tumor barrier
EP1850852A4 (en) * 2005-02-22 2009-11-18 Cedars Sinai Medical Center USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN DISEASE
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
WO2007087575A2 (en) * 2006-01-24 2007-08-02 University Of Chicago Compositions and methods for treating pulmonary hypertension
WO2007138103A1 (en) 2006-06-01 2007-12-06 Nobera Pharma, S.L. Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
EP2246057A1 (en) 2009-04-29 2010-11-03 Nobera Pharma, S.L. Use of allopurinol for the treatment of hand foot skin reaction
JP2013508295A (ja) * 2009-10-16 2013-03-07 デューク・ユニヴァーシティ 薬物誘発性手足症候群を治療するための組成物および方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
almar-plantar erythrodysesthesia(PPE):A literature review with commentary on experience in a cancer centre;Joan D. Webster-Gandy et al.;《European Jouranl of Oncology Nursing》;20071231;全文 *
Severe refractory fingertip ulcerations in a patient with scleroderma:successful treatment with sildenafil;CL Colglazier et al.;《The journal of rheumatology》;20051231;第32卷(第12期);全文 *
Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity;KangWook Lee et al.;《Toxicology》;20081230;第257卷;摘要 *

Also Published As

Publication number Publication date
AU2010306671A1 (en) 2012-05-10
WO2011047256A1 (en) 2011-04-21
JP6063550B2 (ja) 2017-01-18
US20120258970A1 (en) 2012-10-11
AU2010306671B2 (en) 2015-12-17
JP2013508295A (ja) 2013-03-07
JP2016094450A (ja) 2016-05-26
US9220713B2 (en) 2015-12-29
EP2488642A1 (en) 2012-08-22
US20160074405A1 (en) 2016-03-17
US9629845B2 (en) 2017-04-25
EP2488642B1 (en) 2015-03-11
EP2488642A4 (en) 2013-03-06
CN102648279A (zh) 2012-08-22

Similar Documents

Publication Publication Date Title
CN102648279B (zh) 用于治疗药物诱发的手足综合征的组合物与方法
EP3066101B1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
JP2022180461A5 (https=)
CN105338977B (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
JP2010525050A5 (https=)
RU2008152341A (ru) Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии
ES3032941T3 (en) Treatment of hyperinflammatory syndrome
CN1402639A (zh) 药用组合物
TW200940062A (en) Combination comprising paclitaxel for treating ovarian cancer
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
CN114423461B (zh) 组合
Othman et al. Combined Ketamine and Midazolam Versus Midazolam Alone for Initial Treatment of Pediatric Generalized Convulsive Status Epilepticus (Ket-Mid Study): A Randomized Controlled Trial
AU2013362755A1 (en) Uses and methods for the treatment of liver diseases or conditions
US20210330659A1 (en) Use of nicotinamide composition in preparation of drug for treating hand-foot skin reaction induced by sorafenib
CN102781238A (zh) Tivozanib和坦罗莫司的组合
CN111346093B (zh) 拉米夫定、多潘立酮联合用于制备镇静药物的应用
Ypsilantis et al. Attenuation of propofol tolerance conferred by remifentanil co-administration does not reduce propofol toxicity in rabbits under prolonged mechanical ventilation
Kanai et al. Development of new treatment using CMG for oxaliplatin-resistant colorectal cancer with KRAS mutation
CN120569198A (zh) 一种内磺酰胺化合物治疗胆道癌的用途
CN102149389A (zh) 生物素化艾屈肝素用于降低抗血栓治疗期间出血发生率的用途
RU2021128138A (ru) Противораковая терапия с применением соединений 3,5-дизамещенного бензолалкинила и пембролизумаба
Stewart et al. 182 High dose doxorubicin, cisplatin and tamoxifen vs mesothelioma
Stewart et al. 183 Gemcitabine (G), VP16 (V) and cisplatin (P). Phase I study in small cell lung cancer (SCLC)
EA043426B1 (ru) Способ лечения злокачественного новообразования и внутривенный препарат, содержащий abdnaz
KR20190046937A (ko) 만성 골수성 백혈병을 치료 또는 관해하기 위한 의약 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant